LIP
KROS icon

Lighthouse Investment Partners’s Keros Therapeutics KROS Stock Holding History

Lighthouse Investment Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,593
Closed -$503K – 479
2024
Q1 		$503K Buy
+7,593
New +$450K 0.02% 330

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Lighthouse Investment Partners's KROS Position: Q2 2024 in Review

Lighthouse Investment Partners sold out of Keros Therapeutics (KROS) in Q2 2024, closing a stake of 7,593 shares — an estimated $503K sold.

Lighthouse Investment Partners first reported a position in KROS in Q1 2024 and held it in 1 quarter. The position peaked at $503K in Q1 2024. 152 funds tracked by Wall St. Rank hold KROS as of Q2 2024.

  • Lighthouse Investment Partners reported no remaining Keros Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Lighthouse Investment Partners sold 7,593 Keros Therapeutics shares in Q2 2024, an estimated $503K.
  • Lighthouse Investment Partners first reported a position in Keros Therapeutics in Q1 2024 and held it in 1 quarter.
  • Lighthouse Investment Partners's Keros Therapeutics position peaked at $503K in Q1 2024.
  • 152 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2024.

Based on Lighthouse Investment Partners's 13F filing for Q2 2024, filed 14 Aug 2024.